Podcasts about aaic

In the span of a few days, two houses of worship in Minneapolis are facing threats and vandalism.Minneapolis Police are currently investigating the defacing of Temple Israel, a synagogue in Minneapolis. On Monday, a suspect spray-painted swastikas on the doors and pillar of the building. On Friday, Abubakar As-saddique Islamic Center, or AAIC in Minneapolis received an online threat, threatening violence to members of worship at the mosque. Minneapolis police determined the threat to be unfounded, but it still contributed to fear and concern in the Islamic community. Rabbi Marcia Zimmerman, the senior rabbi at Temple Israel and Osman Ahmed, Director of Advocacy with Minnesota's Chapter of the Council on American-Islamic Relations joined Minnesota Now host Nina Moini to talk about their response to the threats.

What's ready for prime time and what's in the pipeline in Alzheimer's disease (AD) diagnosis and care? View conference highlights to find out. Credit available for this activity expires: 8/29/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001535?ecd=bdc_podcast_libsyn_mscpedu

Sebastian Palmqvist, MD, PhD, and Wiesje van der Flier, PhD, cochairs of the 2024 Alzheimer's Association International Conference, speak with JAMA Medical News Lead Senior Staff Writer Rita Rubin, MA, about highlights from the annual meeting, including a blood test for Alzheimer disease, repurposing of a GLP-1 receptor agonist, and the possible brain risk from inhaling wildfire smoke. Related Content: A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke—Highlights From the AAIC

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer's Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN's ongoing efforts to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell's latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio's recent Phase 2/3 Alzheimer's study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio's strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson's and Alzheimer's diseases. “Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer's patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer's research, underscores the importance of our work and the promise it holds for patients.” Join IBN's Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio's recent achievements, the next steps for buntanetap, and the company's future goals. To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com. The latest installment of The Bell2Bell Podcast continues to reinforce IBN's commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN's achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer's Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN's ongoing efforts to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell's latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio's recent Phase 2/3 Alzheimer's study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio's strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson's and Alzheimer's diseases. “Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer's patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer's research, underscores the importance of our work and the promise it holds for patients.” Join IBN's Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio's recent achievements, the next steps for buntanetap, and the company's future goals. To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com. The latest installment of The Bell2Bell Podcast continues to reinforce IBN's commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN's achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

Join StartUp Health NOW for a powerful episode recorded live at the Alzheimer's Association International Conference (AAIC)! We explore the exciting inflection point in Alzheimer's research fueled by AI and machine learning. Hear directly from passionate founders in the StartUp Health Alzheimer's Moonshot Community: Catherine Bornbaum, PhD, CBO at RetiSpec, fresh off the company's $10M Series A, unveils a groundbreaking AI-powered device that analyzes the retina for insights into brain health. Ken Mariash, CEO of Sinaptica Therapeutics, discusses using AI and neuromodulation to potentially slow Alzheimer's and strengthen brain function in healthy individuals. Discover: How AI is unlocking a multi-modal understanding of the brain The potential for revolutionizing treatment for all brain conditions The cutting-edge technologies shaping the future of Alzheimer's research This episode is a must-listen for anyone passionate about brain health and the fight against Alzheimer's! Innovating in Alzheimer's disease? Learn how you can join our Alzheimer's Moonshot. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox. Innovators: Health Transformer University fuels your health moonshot Funders: Become a Health Moonshot Champion

In this podcast we share a few selected highlights from the fourth day of the Alzheimer's Association International Conference (AAIC) taking place in Philadelphia and Online, 28th July to 1st August. Dr Amanda Heslegrave, Principle Research Fellow at University College London, hosts the show with special guests: Dr Darina Petrovsky, Assistant Professor at Duke University Dr Emily Ho, Assistant Professor at Northwestern University Meenakshi Menon, ISTAART Ambassador and incoming PhD student in Cognitive Sciences at Georgia State University The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Main plenary talks from the day included Tara Spires-Jones presenting on 'Synaptic Oligomeric Tau In Alzheimer's Disease — A Potential Culprit In The Spread Of Tau Pathology Through The Brain ', Ricardo F. Allegri on 'Dementia Research In Low- And Middle-Income Countries: Initiatives That Seize Opportunities, Overcome Challenges And Build Capacity'. #AAIC24 -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this podcast we share a few selected highlights from the last day of the Alzheimer's Association International Conference (AAIC) taking place in Philadelphia and Online, 28th July to 1st August. Quang Tran, Science Communications Officer for Alzheimer's Research UK, guest hosts the show with expert panelists: Dr Shea Andrews, Assistant Professor at University of California San Francisco working on Genetic Epidemiology of Alzheimer's disease. Dr Joe Butler, NIHR ARC Research Fellow at University of Sunderland, interested in using techniques and paradigms from experimental psychology to learn about brain health. Roberto A. Guzmán Hernández, ISTAART Ambassador, Graduate Research Assistant and PhD Student at Temple University working on the effects of aggregated tau on endothelial and cerebrovascular dysfunction -- The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Main plenary talks from the day included Michael Weiner 'ADNI: Two Decades Of Impact And The Path Forward', Reisa Sperling ' Preclinical Alzheimer's Disease'. Today was also the first AAIC For ALL, a new format with talks for professional from Jeffrey Cummings on the Therapeutic Landscape, Heather Whitson on The Role Of Blood Tests In Diagnosis And Treatment, Clifford Jack on Criteria For Diagnosis And Staging, Monica Rivera-Mindt on Health Equity And Risk Reduction and Katherine Possin on Dementia Care. Talks for a lay audience from Edward B. Lee on Brain Donation: The Gift Of Knowledge, Hussein Zalzale on The Many Faces Of Alzheimer's Dementia, Subtypes And Unique Features, Dawn Mechanic-Hamilton on How Can We Improve Cognitive Testing? The Answer May Be In The Palm Of Your Hand, Cerise Elliot on Building Inclusive Alzheimer's And Related Dementias Research Studies, Wiesje van der Flier on 'Risk Reduction', Jonathan Schott on 'Diagnosis And Treatment', Nancy Hodgson on 'Dementia Care', Ozioma Okonkwo on 'Health Equity'. #AAIC24 -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Second-quarter earnings season continues with Big Pharma beating Wall Street expectations, the author of an encrypted email sent to BioSpace has a proposal for Moderna and Merck, Roche and Viking seek quicker entry to the obesity market, and AAIC is in full swing. As July comes to a close, biopharma second-quarter earnings continue to roll in with Pfizer, Merck, AbbVie, AstraZeneca and many more reporting. So far, everything is coming up roses with most major companies beating Wall Street expectations. But every rose has its thorn and for biopharma executives this has long been drug price negotiations under the Inflation Reduction Act. Recently, however, drugmakers have expressed confidence that the IRA will not greatly impact their bottom lines. Speaking of bottom lines, in an anonymous email sent to the CFOs of Merck and Moderna and shared with BioSpace, a shareholder made the case that Merck should buy Moderna out of its 50/50 partnership involving Keytruda and their shared investigational personalized cancer vaccine. Meanwhile, M&A activity picked up in the second quarter of 2024 with nearly $18 billion changing hands, according to J.P. Morgan. Q3 has been no stranger to deals so far, either, with Boehringer Ingelheim acquiring Nerio Therapeutics for up to $1.3 billion to boost its immuno-oncology pipeline, and GSK and Flagship Pioneering striking a potential $7B deal to develop a portfolio of novel vaccines and medicines starting with immunology and respiratory treatments. Pfizer raised its full-year outlook after reporting positive Q2 results and announced layoffs this week at two North Carolina sites, with a total of 210 workers losing their jobs. Cuts at the Sanford, N.C. gene therapy manufacturing site come on the heels of Pfizer's Duchenne muscular dystrophy gene therapy failed a Phase III trial. On the obesity front, both Viking Therapeutics and Roche indicated that they will seek entry to the market more quickly than originally anticipated, and the FDA issued a warning on Monday about possible safety risks associated with compounded versions of Novo Nordisk's semaglutide. And the Alzheimer's Association International Conference (AAIC) this week revealed some interesting nuggets, including long-term data regarding Eisai and Biogen's Leqembi, and a small Phase IIb study showing that Novo's GLP-1 liraglutide slowed cognitive decline in Alzheimer's patients by up to 18%.

In this podcast we share a few selected highlights from the first two days of the Alzheimer's Association International Conference (AAIC) taking place in Philadelphia and Online, 28th July to 1st August. Dr Francesca Farina hosts the show with special guests: Dr Annalise Rahman-Filipiak, Assistant Professor, Clinical Neuropsychologist at University of Michigan Dr Tamlyn Watermeyer, NIHR / Alzheimer's Society Dem Comm Fellow at Northumbria University and University of Edinburgh working on cognition and brain health. Dr Merci Best, Research Fellow at the University of Michigan's Paulson Lab, studying the molecular mechanisms of tau-mediated neurodegeneration The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Main plenary talks from the day included Edward B. Lee presenting 'Neuropathology In A Multidisciplinary Age', Timothy Miller on 'Antisense Oligonucleotide Therapeutics For Neurodegenerative Diseases', Henne Holstege delivering a talk titled 'From Longevity To Vulnerability: Genomic Pathways Underlying Cognitive Health In Centenarians And Neurodegenerative Disease'. #AAIC24 @alzassociation -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this podcast we share a few selected highlights from the third day of the Alzheimer's Association International Conference (AAIC) taking place in Philadelphia and Online, 28th July to 1st August. Caitlyn Fastenau,  PhD Candidate at University of Texas Health San Antonio, hosts the show with special guests: Balogun Wasiu, Postdoctoral Associate at University of Pittsburgh Jessica Caldwell, Director, Women's Alzheimer's Movement Prevention and Research Center, Cleveland Clinic Sophia Krix, PhD Student at University of Bonn, working on the ADIS Project The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Main plenary talks from the day included Suvarna Alladi 'Bilingualism And Dementia: Implications For Brain Health And Policy Development', Clive Ballard on 'Psychosis In Alzheimer's Disease'. #AAIC24 -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Join us for another episode of the ISTAART Relay Podcast brought to you by Dementia Researcher. We're releasing one of these shows each week in the build up to the AAIC, which this year starts on the 28th July. In this episode, Dr Diana Karamacoska takes over the hot seat to interview Dr Keir Yong, a Senior Research Fellow at University College London, about the intricacies of Atypical Alzheimer's Disease, and the work of the Atypical Alzheimer's Disease PIA. Discover how posterior cortical atrophy (PCA), a less common variant of Alzheimer's, impacts patients' lives and the innovative research aiming to improve diagnosis and treatment. Get insights into the diagnostic challenges, the role of biomarkers, and the essential interdisciplinary collaborations driving advancements in this field. Don't miss this deep dive into Keir's work, hot topics in the field, and how their PIA is making a difference. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org. Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- You can also enjoy this show as a video on our YouTube Channel at: https://youtu.be/53wt10WyURI -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this episode of the ISTAART Relay Podcast, Dr Jessica Caldwell, a neuropsychologist and director at the Cleveland Clinic, interviews Dr Ece Bayram, the newly appointed assistant professor and incoming communications chair for the ISTAART Lewy Body Dementias PIA. They explore Ece's research on sex differences in genetics and environmental risk factors for Lewy body dementia. Ece shares insights into her innovative projects, the work of their PIA, plans for the upcoming AAIC and the significance of understanding sex and gender differences in neurodegenerative diseases, and the importance of designing research with community involvement. They also discuss the challenges of conducting studies in diverse populations and the need for global collaboration. Tune in to hear about the exciting developments in Lewy body dementia research and the impact of community-driven studies on advancing the field. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org You can also enjoy this show as a video on our YouTube Channel at: https://youtu.be/psSB1wOGSxA -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Welcome to the fifth season of the ISTAART PIA Relay Podcast, brought to you by Dementia Researcher. In this six-part series, members of ISTAART professional interest areas (PIAs) take turns interviewing their colleagues about the latest research in Alzheimer's disease and other dementias. This episode features a Caitlyn Fastenau, a PhD candidate from the University of Texas Health Science Centre interviewing Dr Jessica Caldwell, a neuropsychologist and director of the Women's Alzheimer's Movement Prevention and Research Centre at Cleveland Clinic. Dr Caldwell discusses her pioneering work at the world's only clinic designed specifically for women to reduce their Alzheimer's risk, focusing on sex and gender differences in the disease. She highlights the critical role of menopause, stress, and hormonal changes in Alzheimer's risk and shares insights into the importance of diverse research populations and the unique challenges faced by women caregivers. Tune-in as explore hot topics of sex and gender differences in Alzheimer's research, including the impact of menopause, the need for gender-diverse studies, and the initiatives of the ISTAART Sex and Gender PIA and what they have planned for AAIC. Whether you're a researcher, clinician, or someone affected by Alzheimer's, this episode offers valuable perspectives on the intersections of gender, health, and dementia. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org You can also enjoy this show as a video on our YouTube Channel at: https://youtu.be/E0NWtCyJtzI -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Welcome to the fifth season of the ISTAART PIA Relay Podcast, brought to you by Dementia Researcher. This series features members of ISTAART, engaging in insightful interviews about groundbreaking dementia research, and the work of the ISTAART Professional Interest Areas (PIA) they represent. As we build up to the Alzheimer's Association International Conference in Philadelphia, join us for daily episodes that showcase the remarkable work being done in various research fields. -- In this episode, Professor Arlene Astell interviews Caitlyn Fastenau, a PhD candidate in Integrated Biomedical Sciences focusing on the Biology of Ageing. Caitlyn shares her journey into dementia research, driven by personal experiences and a passion for understanding neurodegenerative diseases. Her research explores the role of immune cells, particularly microglia, in Alzheimer's disease, using advanced techniques like single-cell RNA sequencing. Caitlyn discusses the her work, the importance of diversity in research, highlighting efforts to include underrepresented communities in dementia studies. She also talks about the significance of translational research and the potential non-pharmacological interventions that could reduce the risk of neurodegenerative diseases. Tune in to learn more about the Immunity and Neurodegeneration PIA, what they have planned for AAIC and the latest hot topics in the field, and the collaborative environment that ISTAART provides for researchers at all levels. PS. Don't miss Caitlyn's presentation at the AAIC and her insights on leveraging student engagement in scientific societies. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- You can also enjoy this show as a video on our YouTube Channel at: https://youtu.be/dddOpDsuwlM -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Adam Smith chats with Dr Claire Sexton, Senior Director, Scientific Programs and Outreach from the Alzheimer's Association. Discussing this year's Alzheimer's Association International Conference (AAIC) 28th July to 1st August (+preconference on the 25th – 27th). -- Taking place in-person in Philadelphia and online - the world's leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer's disease. In this exciting edition, we will be giving you an exclusive sneak peek into one of the most highly anticipated events in dementia research conference calendar (also a world first exclusive on the location for 2025). Join us as we explore into how you can attend, the scientific programme, extra events and just what the AAIC will deliver this year. With leading experts, visionary thinkers, and research pioneers gathering under one roof, this conference promises to not only showcase groundbreaking discoveries, but also be a place where you will get careers support, and unrivalled networking opportunities. -- To book your place visit – http://www.aaic.alz.org AAIC for ALL - https://www.alz.org/aaic-for-all/overview.asp Dr Helena Gellersen's blog on getting the most out of AAIC: https://www.dementiaresearcher.nihr.ac.uk/blog-ultimate-guide-to-making-the-most-of-the-aaic -- Students worldwide and researchers from Low- and Middle-Income Countries are now eligible for free ISTAART Membership (and ISTAART members can attend the AAIC Online for Free) - Become a member, then register for the conference if you can't make it in-person. Join ISTAART to get a free online ticket – http://www.istaart.alz.org -- Full biographies on all our guests and a transcript can be found on our website www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you'll find a video version of this podcast with full captions on our YouTube Channel. -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.

Helena Gellersen, narrates her blog written for the Dementia Researcher website. Helena shares valuable tips on making the most of academic conferences, particularly the Alzheimer's Association International Conference (AAIC). She offers practical advice on leveraging conference resources, setting goals, effective networking, and presenting research. She emphasises the importance of preparation, strategic planning, and follow-up to enhance the conference experience and foster meaningful connections, ultimately advancing one's career. Her guidance is particularly beneficial for early career researchers navigating the often overwhelming environment of large academic conferences. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-ultimate-guide-to-making-the-most-of-the-aaic/ -- Dr Helena Gellersen is a Postdoctoral Researcher at the German Center for Neurodegenerative Diseases (DZNE) and current Education Chair Trainee for the ISTAART Neuroimaging. The focus of Helena's work is on identifying preclinical signatures of Alzheimer's disease and to develop novel memory and neuroimaging markers for the early detection of Alzheimer's disease and for monitoring disease progression. @HGellersen Find out more about the Neuroimaging PIA and ISTAART at alz.org/istaart -- Enjoy listening? We're always looking for new bloggers, drop us a line. http://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher

Sára Erzsebet Zsadányi narrates her blog written for Dementia Researcher. Sara shares her thoughts on last months AAIC Neuroscience Next Conference. This hybrid event, designed to bridge local and global scientific communities, has successfully showcased emerging talent in Alzheimer's and dementia research over the past four years. Focusing on inclusivity and accessibility, the conference offers free participation and features multiple hubs worldwide, including Brazil, San Francisco, India, Ireland, Ethiopia, Serbia, and Chicago. It combines live and virtual elements to facilitate broad engagement, emphasising opportunities for early-career researchers. The event's innovative format not only promotes knowledge exchange across continents but also supports economic activities in host locations, thereby broadening the conference's impact beyond the academic sphere. To express an interest in hosting a hybrid hub in 2025, make sure to submit your application. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-a-look-inside-aaic-neuroscience-next/ -- Sára Erzsebet Zsadányi is a PhD Student at the Sant Pau Memory Unit – Neuroimaging Core and Universitat Autonoma de Barcelona. Originally from New Zealand, Sára's current work focusses on neuroimaging of small vessel disease in Down Syndrome. In previous roles she has worked on healthy brain aging and meditation, and is currently an ISTAART Ambassador. -- Enjoy listening? We're always looking for new bloggers, drop us a line. http://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher

In this podcast we learn what to expect from the upcoming AAIC Neuroscience Next Conference, a global, no-cost event that aims to support and showcase the next generation of Alzheimer's and dementia researchers and clinicians. Adam Smith, Dementia Researcher Programme Director is join by some of the people behind making it all happen. Dr Igor Fontana, Alzheimer's Association Director, Scientific Conference Programming. Dr Francesca Farina, Assistant Professor at the University of Chicago and Global Brain Health Institute at Trinity College Dublin, and Dr Kaitlin Seibert, Assistant Professor of Neurology also at University of Chicago. This unique conference works on an innovative "hybrid hub" format that connects both global and local communities. With elements being in-person and online, and full in-person from hubs in the USA, Ireland, India, Ethiopia, Brazil and Serbia. Register for the online event at: https://bit.ly/3mEhcPU Details of registration for an in-person hub are available on our website. -- Full biographies on all our guests and a transcript can be found on our website: https://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you'll find a video version of this podcast with full captions on our YouTube Channel: https://youtu.be/Q4KHRysX3E0 -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support. -- Follow us on Social Media: www.instagram.com/dementia_researcher/ www.facebook.com/Dementia.Researcher/ twitter.com/demrescommunity www.bsky.app/profile/dementiare…archer.bsky.social www.linkedin.com/company/dementia-researcher

Gavin Macgregor-Skinner is a Senior Director at ISSA – The Worldwide Cleaning Trade Association. He has more than 30 years of technical experience in responding to infectious disease outbreaks and emergency management. He is also an Associate Professor in the Department of Public Health Sciences at Penn State College of Medicine and teaches three 15-week graduate courses on Public Health. Macgregor-Skinner has appeared on CNN, Fox News, BBC and many other news outlets to share his expertise on High Consequence Pathogens.   Steven Cooper is an engineer with a technical specialty in the research and development of water-based electrostatic spray systems. He has developed innovative core technology and commercial products related to air-atomizing induction-charging (AAIC) spray systems. Mr. Cooper is an engineer, a scientist, as well as an entrepreneur. He is the co-founder of ByoPlanet/Good Salt LLC, and has been involved in establishing several other successful companies. Mr. Cooper received his undergrad and masters degrees from the University of Georgia and has been continuously involved with the UGA Applied Electrostatics Laboratory for over three decades.

The 2023 Alzheimer's Association International Conference (AAIC) in Amsterdam brought together the world's leading scientists, clinical researchers, early career investigators, caregiving researchers and more to discuss the latest findings and advancements in dementia science. Dr. Percy Griffin joins the podcast to share key highlights from the conference. He discusses the use of CRISPR technology in Alzheimer's research, the significance of defining Alzheimer's by its biology rather than its symptoms and how the field is moving toward a precision medicine approach.  Guest: Percy Griffin, PhD, director of scientific engagement, Alzheimer's Association Show Notes Learn more about the Wisconsin Alzheimer's Disease Research Center's Fall Community Conversation on our website, and watch the livestream on our YouTube page. AAIC is the world's largest forum dedicated to advancing dementia research. Find more highlights from the conference, including on-demand content that is available to watch through September 20, 2023, at 11:59 p.m. CT, on the AAIC website. Find news highlights on CRISPR technology, county-level prevalence data on Alzheimer's, the ACHIEVE study and more mentioned by Dr. Griffin on the AAIC website. Listen to our AAIC 2022 highlights episode with Dr. Griffin, mentioned at 1:15, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen. Learn more about Dr. Griffin in his bio on the Alzheimer's Association's website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

In this podcast we share a few selected highlights from the fourth day of the Alzheimer's Association International Conference (AAIC) taking place in Amsterdam and Online, 16th – 20th July. Adam Smith hosts the show with special guests Vyshnavy Balendra from Saint James School of Medicine, Chicago. Dr Helena Popovi, Family physician, educator and author of three books from the Gold Coast in Australia and Dr Iain Hartnell, Research Communications Officer from Alzheimer's Society. The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. For more information visit: https://aaic.alz.org -- You can also enjoy this show as a video podcast on our YouTube Channel. -- Find more information on our guests, and a full transcript of this podcast on our website at https://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this podcast we share a few selected highlights from the third day of the Alzheimer's Association International Conference (AAIC) taking place in Amsterdam and Online, 16th – 20th July. Adam Smith hosts the show with special guests Dr Jayashree Dasgupta from GBHI Trinity College Dublin, Samita Kirve from Oxford Brookes University and Sarah Gregory from The University of Edinburgh. -- The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. For more information visit: https://aaic.alz.org -- You can also enjoy this show as a video podcast on our YouTube Channel. -- Find more information on our guests, and a full transcript of this podcast on our website at https://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this podcast we share a few selected highlights from the second day of the Alzheimer's Association International Conference (AAIC) taking place in Amsterdam and Online, 16th – 20th July. Adam Smith hosts the show with special guests Sára Erzsebet Zsadányi from Universitat Autònoma de Barcelona, Dr Sonata Mačiulskytė from Klaipeda University and Dr Aoife Cosgrave from Alzheimer's Research UK. -- The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. For more information visit: https://aaic.alz.org -- You can also enjoy this show as a video podcast on our YouTube Channel. -- Find more information on our guests, and a full transcript of this podcast on our website at https://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this podcast we share a few selected highlights from the first day of the Alzheimer's Association International Conference (AAIC) taking place in Amsterdam and Online, 16th – 20th July. Adam Smith hosts the show with special guests Dr Mizuki Morisaki from University of Bristol, Sam Keat, PhD Student in the UK Dementia Research Institute at Cardiff University and Dr Arunima Sikdar a Postdoc Research Associate from University of North Carolina. -- The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. For more information visit: https://aaic.alz.org -- You can also enjoy this show as a video podcast on our YouTube Channel. -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

With an Accelerated nod for Aduhelm (aducanumab) and now full approval for Leqembi (lecanemab) in the USA, Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523) have overturned decades of failure in Alzheimer's.But at the annual meeting of the Alzheimer's Association (AAIC), it's another neurology heavyweight taking center stage, as Eli Lilly (NYSE: LLY) makes clear its intention to remain a leader in the treatment of this challenging disease.At the AAIC in Amsterdam, we're speaking with two key figures from the development program for donanemab, a candidate which could slow cognitive decline for millions of people with early Alzheimer's, while generating billions in annual revenues.Lilly is presenting full results from a key Phase III trial of its antibody, which like Leqmebi, clears aberrant proteins from the brain with the goal of combatting neurodegeneration.There are important differences between the way the two molecules work, however, and Lilly is confident its approach, which includes limited duration dosing, offers the best chance of success.The new data, which form part of a regulatory submission for approval in the USA, seem to bear this out. As with other therapies in this class, all eyes will be on safety, and Lilly hopes that “treating to clear,” and then holding off on dosing, could help avoid side effects.Like Eisai, Lilly is also interested in developing a subcutaneous treatment in future, with early data for another molecule, remternetug, showing strong potential in this regard.We discuss all of this and more, in Episode 24 of The Pharma Letter Podcast.

In the runup to the annual meeting of the Alzheimer's Association, this week we are speaking with Michael Irizarry, deputy chief clinical officer at Eisai US.At the event in July, there will be plenty to discuss, with recent new data from Eli Lilly (NYSE: LLY) suggesting its anti-amyloid candidate, donanemab, is likely to provide healthy competition for Eisai's (TYO: 4523) own Alzheimer's product, lecanemab - marketed in the USA as Leqembi.Like Lilly, Eisai has been a pioneer in neurology, sticking with its Alzheimer's research even when times were tough and it looked like a clinical breakthrough would never come.That we are now talking about potentially three approved products for early Alzheimer's shows how quickly development has advanced - as both Lilly and Eisai look ahead to the possibility of offering more beneficial subcutaneous treatments in future.In the podcast this week, we will discuss Eisai's upcoming presentations at AAIC and consider what the future might hold for the treatment of Alzheimer's.

Ajantha Abey narrates his blog written for Dementia Researcher. In "A Beginner's Guide to Preparing for a Big Conference," (with the AAIC around the corner) Ajantha advises on strategies to make the most of conferences. They stress the importance of planning, setting goals, and prioritizing sessions. The guide offers tips for effective networking, taking notes, and scheduling rest afterwards. Overall, the he emphasises the value of being prepared and organised to navigate conferences successfully. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/guest-blog-a-beginners-guide-to-preparing-for-a-big-conference/ -- Ajantha Abey is a PhD student in the Kavli Institute at University of Oxford. He is interested in the cellular mechanisms of Alzheimer's, Parkinson's, and other diseases of the ageing brain. Previously, having previoulsy explored neuropathology in dogs with dementia and potential stem cell replacement therapies. He now uses induced pluripotent stem cell derived neurons to try and model selective neuronal vulnerability: the phenomenon where some cells die but others remain resilient to neurodegenerative diseases. -- Enjoy listening and reading our blogs? We're always on the look out for new contributors, drop us a line and share your own research and careers advice dementiaresearcher@ucl.ac.uk This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support.

Adam Smith chats with Dr Claire Sexton, Senior Director, Scientific Programs and Outreach from the Alzheimer's Association. Discussing this year's Alzheimer's Association International Conference (AAIC) 16 – 20 July. -- Taking place in-person in Amsterdam and online - the world's leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer's disease. In this exciting edition, we will be giving you an exclusive sneak peek into one of the most highly anticipated events in dementia research conference calendar. Join us as we delve into how you can attend, the scientific programme, extra events and just what the AAIC will deliver this year. With leading experts, visionary thinkers, and research pioneers gathering under one roof, this conference promises to not only showcase groundbreaking discoveries, but also be a place where you will get careers support, and unrivalled networking opportunities. -- To book your place visit - https://aaic.alz.org Join ISTAART to get a free online ticket – https://istaart.alz.org -- Note: Students worldwide and researchers from Low- and Middle-Income Countries are now eligible for free ISTAART Membership (and ISTAART members can attend the AAIC Online for Free) - Become a member, then register for the conference if you can't make it in-person. Full biographies on all our guests and a transcript can be found on our website www.dementiaresearcher.nihr.ac.uk -- Register to attend the Alzheimer's Society, Alzheimer's Research UK, Dementias Platform UK and UK Dementia Research Institute Networking event: https://www.smartsurvey.co.uk/s/U2N2WG/ -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you'll find a video version of this podcast with full captions on our YouTube Channel. -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.

In today's episode, Dr Chi Udeh-Momoh, Research Programme and Biomarker Lead at Imperial College London and GHBI Fellow at University California, San Francisco talks to a line-up of captivating guests as we dive into sharing insights from the AAIC Satellite Symposium 2023 – focussing on the latest research from Latin America. -- This week's guests are all currently GBHI Fellows, and highly respected researchers at their home institutions: Dr Adolfo M. García, Director, Cognitive Neuroscience Center, Universidad de San Andres / Senior Atlantic Fellow, Global Brain Health Institute, University of California, San Francisco / Associate Researcher, Universidad de Santiago de Chile. Adolfo specializes in language in neurodegenerative diseases. Dr Alison Canty, Associate Professor, & Atlantic Fellow for Equity in Brain Health at Global Brain Health Institute, Trinity College Dublin / Wicking Dementia Research and Education Centre, University of Tasmania. Alison is researching Neuroplasticity in ageing and neurodegenerative disease. Dr Jayashree Dasgupta, is a GBHI Fellow and Clinical Psychologist working on translating evidence based practices to develop services for mental well-being, active aging and dementia care in India. She is also an ethics researcher and my work involves highlighting perspectives from under-represented settings into clinical research. Michelle Moses-Eisenstein, Atlantic Fellow for Equity in Brain Health and Performing Artist at Global Brain Health Institute, University of California, San Francisco. Michelle is committed to improving the lives of people with dementia and their care partners through innovation across arts programs, grants, communications, and policy. She is a creative and empathetic problem solver motivated to achieve public health solutions and health equity through relationship building, advocacy, education, stakeholder engagement, and strategic partnerships. Dr Chi Udeh-Momoh, Research Programme and Biomarker Lead and currently GHBI Fellow. Chi was I was born in Nigeria and relocated to the UK as a teenager. She has always been fascinated by the brain - how we think, learn and remember; and how these processes can be affected in disease/ alleviated therapeutically. Chi studied Neuroscience all the way through undergrad to PhD, then did my post-doc in neuroepidemiology, her focus is now on Dementia Prevention and biomarkers. -- For more information on the event visit: https://www.alz.org/satellite-symposium/overview.asp For more information on GBHI visit: https://www.gbhi.org/events/gbhi-annual-conference-2023 -- Full biographies on all our guests and a transcript can be found on our website https://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you'll find a video version of this podcast with full captions on our YouTube Channel – https://youtu.be/zy7mKB49vuw -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.

On this week's Cyber Report, sponsored by Fortress Information Security, John Cofrancesco, the founder of AAIC, an innovative company that uses AI to monitor cyber networks, discusses the threat posed by TikTok, how to mitigate the threat from such invasive apps, the looming threat from Russia as allied nations increase assistance to Ukraine, what to expect from the Biden administration's upcoming National Cyber Strategy and more with Defense & Aerospace Report Editor Vago Muradian.

There Must be an Actual Change in the Appearance, Shape, Color, Or Other Material Aspect Of The Property for Coverage to Apply Plaintiff MTDB Corporation d/b/a Striker Lanes (MTDB) sued seeking declaratory judgment action against defendant, American Auto Insurance Company (AAIC), seeking a declaration that AAIC owed it coverage for alleged business losses and property damage due to the COVID-19 pandemic. In MTDB Corporation D/B/A Striker Lanes v. American Auto Insurance Company, 2022 IL App (1st) 210979-U, No. 1-21-0979, Court of Appeals of Illinois, First District, Sixth Division (December 30, 2022) the Illinois Court of Appeal followed the Illinois Supreme Court requiring actual physical damage to property and refused coverage to the plaintiff. BACKGROUND MTDB sought coverage under the property coverage and the civil authority endorsement provisions of the policy. The policy at issue provided property, general liability, and automobile coverages for the policy period of August 19, 2019, to August 19, 20202. The relevant portions of the policy and Section A of the business income coverage form states that: "[w]e will pay for the actual loss of business income you sustain due to the necessary suspension of your operations during the period of restoration. The suspension must be caused by direct physical loss of or damage to property at the premises described in the Declarations, including personal property in the open (or in a vehicle) within 100 feet, caused by or resulting from any Covered Cause of Loss." --- Support this podcast: https://podcasters.spotify.com/pod/show/barry-zalma/support

AAIC Special Series Part 8: Closing out our special series spotlighting the 2022 Alzheimer's Association International Conference, Dr. Percy Griffin joins the podcast to discuss highlights from this year's event. Guest: Percy Griffin, PhD, director, scientific engagement, Alzheimer's Association Show Notes Find more highlights from the conference, including on-demand content that is available to watch through September 1, 2022 at 11:59p.m. PT , at the AAIC website. Learn more about Dr. Percy Griffin at his bio on the Alzheimer's Association website. Listen to our AAIC special series episode with Dr. Carl Hill, mentioned by Dr. Chin at 3:41, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen. Listen to our AAIC special series episode with Dr. Heather Snyder, mentioned by Dr. Chin at 18:22, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen Find the news highlights on diet, racism, preeclampsia, COVID-19, and more mentioned by Dr. Chin at the AAIC website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

Coverage from the Alzheimer's Association International Conference (AAIC) bringing together early career researchers to share their conference highlights. In the last of this weeks special shows, Dr Natasha Clarke from Centre de recherche de l'Institut universitaire de gériatrie de Montréal chairs the discussion with Dr Richard Lofthouse from University of Aberdeen, Dr Diana Karamacoska from Western Sydney University and Anqesha Murray, at Rensselaer Polytechnic Institute, New York. Sharing highlights from the third day of the world's largest dementia conference. Follow the conference live at #AAIC22 You can find out more about our panellists, and their work on our website. There you will also find a full transcript: www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

Coverage from the Alzheimer's Association International Conference (AAIC) bringing together early career researchers to share their conference highlights. In today's show, Dr Sarah Bauermeister from University of Oxford hosts, with guests Dr Claire Lancaster from University of Sussex, Esther Hui from University College London and and Dr Darina Petrovsky, Rutgers University Sharing highlights from the third day of the world's largest dementia conference. Follow the conference live at #AAIC22 You can find out more about our panellists, and their work on our website. There you will also find a full transcript: www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

Coverage from the Alzheimer's Association International Conference (AAIC) bringing together four attendees to chat over coffee, and share their highlights. In todays show, we welcome back Dr Isabel Castanho to take her first turn in the hosts chair, with special guests and show newcomers Dr Annalise Rahman-Filipiak from University of Michigan, Dr Connor Richardson from Newcastle University and Dr Bhargav Teja Nallapu from Albert Einstein College of Medicine. Sharing highlights from the second day of the worlds largest dementia conference. Follow the conference live at #AAIC22 You can find out more about our panellists, and their work on our website. There you will also find a full transcript: https://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

For the first time since 2019, we're back at the Alzheimer's Association International Conference (AAIC) in-person – which means we can bring together attendees to chat over coffee, and share their highlights. In todays show, long-time listener and contributor, Sarah Gregory from the University of Edinburgh is our guest host, talking with Dr Ríona McArdle, from Newcastle University, Dr Lillian Hung from University of British Columbia and Dr Sarah-Naomi James from University College London. Sharing highlights from the Tech and Dementia Preconference session and the first day, with a focus on equality, diversity and inclusion, and co-production. Follow the conference live at #AAIC22 You can find out more about our panellists, and their work on our website. There you will also find a full transcript: www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

AAIC Special Series Part 7: Recent studies have shown that 1 in 5 U.S. adults who were diagnosed with COVID-19 now deal with Long COVID, a condition where individuals report fatigue, cognitive issues, difficulty breathing, and other symptoms lasting at least three months after infection. With these reported effects on cognition and brain health, what else do we know about COVID's impact on the brain? Dr. Heather Snyder joins us to talk about what we know about COVID-19's effects on the brain and her upcoming scientific session at AAIC 2022. Guest: Heather Snyder, PhD, vice president, medical & scientific relations, Alzheimer's Association Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Read more about Dr. Snyder at her bio on the Alzheimer's Association website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 6: Dr. Krista Lanctôt joins the podcast to discuss apathy, how it develops in people with Alzheimer's disease, and her upcoming AAIC 2022 plenary talk. Guest: Krista Lanctôt, PhD, senior scientist, Sunnybrook Health Sciences Centre, full professor, University of Toronto Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Lanctot at her bio on the University of Toronto website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 5: Bringing together scientists, clinicians, and research participants from all over the world, AAIC 2022 showcases the work and experiences of people from unique backgrounds and perspectives and highlights the importance of diversity in Alzheimer's disease research. Dr. Carl Hill joins the podcast to discuss why diversity is important in scientific research and how AAIC 2022 supports efforts to make Alzheimer's disease research more equitable and inclusive. Guest: Carl Hill, PhD, MPH, chief diversity, equity and inclusion officer, Alzheimer's Association Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Listen to our past episode of Dementia Matters with Dr. Carl Hill on our website, Spotify, Apple Podcasts, YouTube, or wherever you get your podcasts.  Learn more about Dr. Carl Hill on the Alzheimer's Association website. Learn more about Henrietta Lacks' story (mentioned by Dr. Hill at 8:53) by checking out the Mind Readers Book Club discussion about the book, The Immortal Life of Henrietta Lacks, on our YouTube page. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 4: Research into delirium, a condition where older adults experience acute confusional states during hospitalizations, and its connections to dementia have led to  numerous advancements in hospital care and treatments. Dr. Sharon Inouye joins the podcast to discuss how our understanding of delirium has changed over the past 30 years and previews her upcoming AAIC plenary talk about the intersection of delirium and dementia. Guest: Sharon Inouye, PhD, director, Aging Brain Center, Hinda and Arthur Marcus Institute for Aging Research, professor, Harvard Medical School Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Inouye at her bio on the Marcus Institute for Aging Research website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 3: Mild cognitive impairment (MCI) is an early stage of memory loss and cognitive impairment that can develop into dementia. While physicians have medications they can prescribe to manage the condition, many researchers and doctors are focusing on lifestyle interventions that could support a person's cognition and address behavioral changes. Dr. Linda Lam joins the podcast to discuss her work studying mild cognitive impairment and preview her upcoming AAIC plenary talk on non-pharmacological treatments for MCI and dementia. Guest: Linda Lam, MBChB, MD, professor, Chinese University of Hong Kong Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Linda Lam on the Chinese University of Hong Kong website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 2: Attending scientific conferences is usually a major commitment, often requiring attendees to travel, pay attendance fees, and take time out during the day to learn about groundbreaking research. Recent conferences like the Alzheimer's Association International Conference (AAIC) are opening their doors virtually to make the events more accessible to research participants, care partners, and the general public. Sarah Walter joins the podcast as part of our special series previewing AAIC 2022 to discuss her article on how virtual scientific conferences impact research participant engagement and why it's important for participants to hear about the research they're involved in. Guest: Sarah Walter, MSc, program administrator, Alzheimer's Clinical Trials Consortium, Alzheimer's Therapeutic Research Institute, University of Southern California Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Read Walter's article, “Can Virtual Scientific Conferences Facilitate Two-Way Learning between Dementia Researchers and Participants?” through the National Library of Medicine. Learn more about Sarah Walter on the Alzheimer's Clinical Trials Consortium website. Connect with us   Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 1: To kick off our month-long special series previewing the 2022 Alzheimer's Association International Conference, or AAIC, we've invited  Claire Sexton, senior director of the Alzheimer's Association's scientific programs, to join us to discuss the goals of AAIC, how the pandemic impacted the influential conference, and what she's looking forward to at this year's event. Guest: Claire Sexton, DPhil, senior director of scientific programs and outreach, Alzheimer's Association Show Notes The AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Claire Sexton on the Alzheimer's Association website. Connect with us Find transcripts and more at our website. Email Dementia Matters at dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

In this weeks podcast, Adam Smith speaks with Alzheimer's Association Director, Scientific Programs and Outreach, Dr Claire Sexton. Discussing this years Alzheimer's Association International Conference (AAIC) July 31 - August 4 2022. Taking place in-person in San Diego, USA and online - the world's leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer's disease. Learn what the organisors have planned for this years event, new features and about some of the amazing sessions planned for those attending in-person and online. Students worldwide and researchers from Low and Middle Income Countries are now eligable for free ISTAART Membership (and ISTAART members can attend the AAIC Online for Free) - Become a member, then register for the conference if you can't make it in-person. To book your place visit - https://aaic.alz.org/ Join ISTAART to get a free online ticket - www.alz.org/istaart A transcript of this podcast is also available here https://www.dementiaresearcher.nihr.ac.uk/podcast-aaic-2022-preview/ Dr Claire Sexton Bio https://www.dementiaresearcher.nihr.ac.uk/profile-dr-claire-sexton/ Adam Smith Bio https://www.dementiaresearcher.nihr.ac.uk/podcast-profile-adam-smith/ _________________________ Finally, please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. Register on our website to receive your weekly bulletin, and to access more great content – blogs, science, career support + much more www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

The venture capitalist, co-founder of big data company Palantir, said at an event in Miami on Wednesday that the way to AGI is going to get surveillance AI, which he called "communist totalitarian technology". https://www.cnbc.com/2021/10/22/palantirs-peter-thiel-surveillance-ai-is-more-concerning-than-agi.html The cooperation between the Air Force Research Laboratory and the British Defense Science and Technology Laboratory (Dstl) is part of a four-year Autonomy and Artificial Intelligence Collaboration (AAIC) partnership agreement signed in December 2020. https://www.defensenews.com/artificial-intelligence/2021/10/20/us-air-force-teams-with-uk-on-machine-learning-demo/ Gary Peters, D-Mich., And Rob Portman R-Ohio, have introduced laws to protect information processed by government contractors who use artificial intelligence technologies. https://www.fedscoop.com/lawmakers-introduce-bill-to-increase-oversight-of-federal-contractors-use-of-ai/ A college racing team from Germany won the Autonomous Competition at Indianapolis Motor Speedway on Saturday after its algorithm code produced an estimated lap time of 129.2 kilometers per hour, which corresponds to 80 miles per hour. https://www.sporttechie.com/driver-less-car-hits-80-mph-to-win-autonomous-competition-at-the-brickyard# Covid-19 has put the spotlight on many networks in the world, from the internet to international air travel. https://www.technologyreview.com/2021/10/26/1038643/ai-reinforcement-learning-digital-twins-can-solve-supply-chain-shortages-and-save-christmas/ Visit www.integratedaisolutions.com

Podcast jest dostępny także w formie newslettera: https://ainewsletter.integratedaisolutions.com/ Inwestor venture capital, który był współzałożycielem firmy Palantir zajmującej się dużymi danymi, powiedział na spotkaniu w Miami w środę, że na drodze do AGI otrzymuje się sztuczną inteligencję, którą określił jako „komunistyczną technologię totalitarną”. https://www.cnbc.com/2021/10/22/palantirs-peter-thiel-surveillance-ai-is-more-concerning-than-agi.html Współpraca między Air Force Research Laboratory i brytyjskim Defense Science and Technology Laboratory (Dstl) https://www.defensenews.com/artificial-intelligence/2021/10/20/us-air-force-teams-with-uk-on-machine-learning-demo/ Gary Peters, D-Mich. https://www.fedscoop.com/lawmakers-introduce-bill-to-increase-oversight-of-federal-contractors-use-of-ai/ Kolegialny zespół wyścigowy z Niemiec wygrał sobotnie zawody autonomiczne na torze Indianapolis Motor Speedway po tym, jak jego kod algorytmu wygenerował szacowany czas okrążenia 129,2 km na godzinę, co odpowiada 80 mil na godzinę. https://www.sporttechie.com/driver-less-car-hits-80-mph-to-win-autonomous-competition-at-the-brickyard# Covid-19 zwrócił uwagę na wiele światowych sieci, od internetu po międzynarodowe podróże lotnicze. https://www.technologyreview.com/2021/10/26/1038643/ai-reinforcement-learning-digital-twins-can-solve-supply-chain-shortages-and-save-christmas/ Odwiedź www.integratedaisolutions.com

Der Risikokapitalgeber, Mitbegründer der Big-Data-Firma Palantir, sagte am Mittwoch bei einer Veranstaltung in Miami, dass man auf dem Weg zu AGI Überwachungs-KI bekomme, die er als "kommunistische totalitäre Technologie" bezeichnete. https://www.cnbc.com/2021/10/22/palantirs-peter-thiel-surveillance-ai-is-more-concerning-than-agi.html Die Kooperation zwischen dem Air Force Research Laboratory und dem britischen Defence Science and Technology Laboratory (Dstl) ist Teil einer im Dezember 2020 unterzeichneten vierjährigen Autonomy and Artificial Intelligence Collaboration (AAIC)-Partnerschaftsvereinbarung. https://www.defensenews.com/artificial-intelligence/2021/10/20/us-air-force-teams-with-uk-on-machine-learning-demo/ Gary Peters, D-Mich., und Rob Portman R-Ohio, haben Gesetze zum Schutz von Informationen eingeführt, die von staatlichen Auftragnehmern verarbeitet werden, die Technologien der künstlichen Intelligenz verwenden. https://www.fedscoop.com/lawmakers-introduce-bill-to-increase-oversight-of-federal-contractors-use-of-ai/ Ein College-Rennteam aus Deutschland gewann am Samstag den Autonomous Competition auf dem Indianapolis Motor Speedway, nachdem sein Algorithmus-Code eine geschätzte Rundenzeit von 129,2 Stundenkilometern, das entspricht 80 Meilen pro Stunde, produzierte. https://www.sporttechie.com/driver-less-car-hits-80-mph-to-win-autonomous-competition-at-the-brickyard# Covid-19 hat viele Netzwerke der Welt ins Rampenlicht gerückt, vom Internet bis zum internationalen Flugverkehr. https://www.technologyreview.com/2021/10/26/1038643/ai-reinforcement-learning-digital-twins-can-solve-supply-chain-shortages-and-save-christmas/ Visit www.integratedaisolutions.com

Dr. Snyder of the Alzheimer's Association spoke to me about long-term cognitive effects from Covid-19 and diversity issues in clinical trials.   I was honored to interview two renowned people from the Alzheimer's Association before the start of this year's International Conference. The AAIC is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next-generation investigators, clinicians, and the care research community to share research discoveries that'll lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer's disease. My second guest was Heather M. Snyder, Ph.D. Dr. Snyder is vice president, Medical & Scientific Relations at the Alzheimer's Association. In this role, she oversees Association initiatives that accelerate innovative Alzheimer's research and provide opportunities for the global dementia community to connect and collaborate. Topics Discussed Dr. Snyder is responsible for the progress the Association has made in Alzheimer's and dementia research funding. We discussed Covid-19s Association with long-term risk of cognitive dysfunction and the possibility of accelerating Alzheimer's symptoms. People with the virus experience short- and/or long-term neuropsychiatric symptoms, including loss of smell and taste and cognitive and attention deficits, known as "brain fog." For some, these neurological symptoms persist, and researchers are working to understand the mechanisms by which this brain dysfunction occurs and what that means for cognitive health long term. Our second topic was the need for greater diversity in clinical trials. A significant hurdle in developing therapeutics and care models for Alzheimer's disease that work for people of all ethnic and racial backgrounds is recruiting and retaining traditionally underrepresented groups in clinical trials. If you're looking to increase your awareness of the efforts on the part of the Alzheimer's Association, this is the episode to tune in and hear. TRANSCRIPT Related Episodes A Ray of Hope? Stabilizing Cognitive Decline   NeuroReserve - Helping Our Brainspan Match our Lifespan NeuroReserve - Helping Our Brainspan Match our Lifespan   Be sure to check out our website for more resources, partners, recipes, and more.  www.fadingmemoriespodcast.com Join Fading Memories On Social Media! If you've enjoyed this episode, please share this podcast with other caregivers!  You'll find us on social media at the following links. Facebook    Instagram    Twitter Subscribe to our YouTube channel. There you can see me in "action" and watch the bonus videos I share. Want to learn from Jennifer in person (or virtually)? Wherever you'd like a training session, Jen is available. Contact her at fadingmemoriespodcast@gmail.com    

Rebecca M. Edelmayer, Ph.D guided me through topics on air pollution, education and Transgender risks for Alzheimer's.   I was honored to interview two renowned people from the Alzheimer's Association before the start of this year's International Conference. The AAIC is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next-generation investigators, clinicians, and the care research community to share research discoveries that'll lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer's disease. My first guest is Rebecca M. Edelmayer, Ph.D. As senior director, Scientific Engagement for the Alzheimer's Association. You can read her bio here. Topics Covered Dr. Edelmayer and I discussed three topics that were presented at the conference. First up is how improving air quality reduces dementia risk. Both increasing levels of air pollution and increasing cases of dementia are worldwide public health crises. While research has previously linked air quality and cognition, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health. Our second topic discussed was how an increase in education could lower your dementia risk. However, the increase in education is offset by poor lifestyle choices like smoking. Our third and final topic covered focused on the transgender community. According to two studies presented at the conference, Transgender and gender nonbinary adults in the U.S. are more likely to report worsening memory and thinking functional limitations and depression than cisgender (non-transgender) adults. Curious Minds Will Tune In I found this topic fascinating, and I learned a few new things. I haven't had many interactions with the transgender community and none when we're talking about Alzheimer's. If you're interested in furthering your knowledge about the potential causes and preventions of Alzheimer's, this is the episode to tune in and hear. TRANSCRIPT Related Episodes: Hope on the Horizon? (Research Interview) Are We Closer to a Cure? NeuroReserve - Helping Our Brainspan Match our Lifespan NeuroReserve - Helping Our Brainspan Match our Lifespan   Be sure to check out our website for more resources, partners, recipes, and more.  www.fadingmemoriespodcast.com Join Fading Memories On Social Media! If you've enjoyed this episode, please share this podcast with other caregivers!  You'll find us on social media at the following links. Facebook    Instagram    Twitter Subscribe to our YouTube channel. There you can see me in "action" and watch the bonus videos I share. Want to learn from Jennifer in person (or virtually)? Wherever you'd like a training session, Jen is available. Contact her at fadingmemoriespodcast@gmail.com  

Hideki Garren MD Ph.D. is the Chief Medical Officer at Prothena with a mission to advance the pipeline of candidates for neurodegenerative and protein amyloid diseases, including Alzheimer's and Parkinson's.  We talk about the recent FDA approval of aducanumab and its impact on research. Hideki says, "As we've shown at the AAIC, the Alzheimer's Association International Conference last week in Denver, we highlighted two out of three of our Alzheimer's disease potential treatments. One of them is PRX012, which is our anti-Aβ antibody. The second one that we showed there was a dual, Aβ-tau vaccine. And then thirdly, we have an anti-tau antibody, which is being developed. It was not shown at the AAIC, but we're also developing that. So these three molecules we're developing for Alzheimer's disease. And this momentum has really applied to us as well." #Prothena #Alzheimers #aduhelm #ProteinAmyloidDiseases #NeurodegenerativeDiseases #Vaccines #AAIC21 Prothena.com Listen to the podcast here

Hideki Garren MD Ph.D. is the Chief Medical Officer at Prothena with a mission to advance the pipeline of candidates for neurodegenerative and protein amyloid diseases, including Alzheimer's and Parkinson's.  We talk about the recent FDA approval of aducanumab and its impact on research. Hideki says, "As we've shown at the AAIC, the Alzheimer's Association International Conference last week in Denver, we highlighted two out of three of our Alzheimer's disease potential treatments. One of them is PRX012, which is our anti-Aβ antibody. The second one that we showed there was a dual, Aβ-tau vaccine. And then thirdly, we have an anti-tau antibody, which is being developed. It was not shown at the AAIC, but we're also developing that. So these three molecules we're developing for Alzheimer's disease. And this momentum has really applied to us as well." #Prothena #Alzheimers #aduhelm #ProteinAmyloidDiseases #NeurodegenerativeDiseases #Vaccines #AAIC21 Prothena.com Download the transcript here

In this episode, Sarah presents three ways that Alzheimer's trials will change now that Biogen's Aduhelm (aducanumab) has been approved by the FDA. The team discusses whether placebo-controlled trials are still ethical and how ongoing dementia studies can manage patient attrition. Can trials pivot to allow patients to aducanumab as a background therapy?The hosts also discuss how the price of aducanumab may limit patient access, and what it might take for payers to cover the cost of this pricey drug. Read the full article here: AAIC 2021: Six Ways the Approval of Aducanumab Will Change Alzheimer's Clinical TrialsFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this episode, Ayesha discussed a presentation at this year's Alzheimer's Association International Conference (AAIC) 2021 about the impacts of COVID-19 on cognitive health. The study, conducted at New York University Langone Health, found that in cognitively normal COVID-19 patients that experienced the neurological symptom of confusion due to toxic-metabolic encephalopathy (TME), levels of serum biomarkers associated with neuroinflammation, neuronal injury and Alzheimer's disease (such as phosphorylated Tau 181 and neurofilament light protein) were higher than in patients that did not have TME. The strong correlation of these serum biomarkers with the presence of neurological symptoms in COVID-19 patients suggest that COVID-19 patients could experience an acceleration of AD/ADRD symptoms and pathology.Ayesha also discussed another story about serum biomarkers for the early detection of pancreatic cancer. Immunovia, a Swedish biotech firm, has developed a nine-panel biomarker blood test that can be used for the detection of pancreatic in early stages. The company's American subsidiary, located in Massachusetts, received approval for the test early this month and the Massachusetts Department of Public Health has already begun using it to test patients for the deadly cancer. The test evaluates a combination of immunoregulatory and tumor biomarkers. Early detection of pancreatic cancer is a significant unmet clinical need because the cancer is typically diagnosed in late stages when treatment options are limited and the disease is difficult to treat.AAIC 2021: Insights into COVID-19 Impacts on Cognitive HealthImmunovia's Pancreatic Cancer Blood Test is World's First for Early Disease DetectionFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

There are plenty of drugs both legal and illegal that people use every day. For some it's a casual thing, for others it's a debilitating practice that consumes their thoughts. Drugs appear to be a gateway to escaping reality, but is it really that simple? Josh talks with a recovered ice addict, the head of an addiction lab, and revisits his own past to find out more. Dive deep into the rush... of drugs. If this episode has affected you in any way, you can call the National Alcohol and Other Drug Hotline for free and confidential advice about alcohol and other drugs on 1800 250 015, or chat online via The Alcohol & Drug Information Service (ADIS) Web Chat https://yourroom.health.nsw.gov.au/getting-help/Pages/ADIS-Web-Chat.aspx  LINKS Josh Szeps @joshszeps Nova Podcasts Instagram @novapodcastsofficial Prof Andrew Lawrence https://florey.edu.au/science-research/scientist-directory/professor-andrew-lawrence  Australian Anti Ice Campaign https://australianantiicecampaign.org.au/  Naitonal Support Line 1800 NO TO ICE (1800 66 86 423) CREDITS Host: Josh Szeps Managing Producer: Elle Beattie Producer: Amy Kimball Editor: Adrian Walton See omnystudio.com/listener for privacy information.

Hideki Garren, MD, PhD, Chief Medical Officer at Prothena discusses data from two presentations at the Alzheimer's Association International Conference (AAIC); PRX012, Prothena's next generation anti-amyloid beta (Aβ) antibody and the dual Aβ-tau vaccine being developed for the prevention and treatment of Alzheimer's Disease (AD). He talks about the company's approach to addressing the AD global healthcare crisis. #Alzheimer #AAIC H​ideki Garren, M.D., Ph.D.​, Chief Medical Officer​. Dr. Garren has served as our Chief Medical Officer since April 2021. Before joining Prothena, between 2013 and 2021 Dr. Garren was with F. Hoffmann-La Roche Ltd. (Roche) & Genentech Inc. and most recently served as Vice President, Global Head of Neuroimmunology with responsibility for leading Roche's Neuroimmunology franchise team. Prior to Roche, between 2011 and 2013, Dr. Garren held the role of Executive Director, Translational Medicine Expert in Neuroscience with Novartis Pharma. Dr. Garren also served as Co-Founder, Executive Vice President, Chief Scientific Officer, and Chief Operating Officer of Bayhill Therapeutics, Inc., a company he started in 2002 based on a technology platform he co-invented while at Stanford University. He currently serves on the board of directors of Coya Therapeutics, a privately-held clinical-stage biotechnology company. Dr. Garren earned his Bachelor of Science from the California Institute of Technology and his MD and PhD from the University of California, Los Angeles (UCLA). He completed his internship in internal medicine at UCLA, and his residency in neurology and fellowship in neuroimmunology at Stanford University.

In this episode, Sarah talked about attending the Alzheimer's Association International Conference (AAIC) 2021 virtually this year and discussed increasing diversity in Alzheimer's clinical trials as an important topic that was part of the conference. Black and Hispanic people are more likely to be diagnosed with Alzheimer's compared to Caucasians. Sarah outlined the results of some studies shared at the meeting, including a study that revealed people of minority backgrounds would be more likely to participate in a trial if they were directly invited to participate by someone of their own race, and if a family member had the disease. Exclusion criteria could also inadvertently exclude potential participants based on race, warranting the need for trial designs that foster greater inclusivity, including outreach tools, to broaden recruitment.Related to the theme of racial inequities in healthcare as well as the health and beauty industry, Ayesha discussed a recent lawsuit launched against Johnson & Johnson over its iconic baby powder by a Black women's advocacy group. The group claims that the company engaged in targeted marketing of their baby powder to Black and Hispanic women, whilst knowing for decades about asbestos impurities in their product; the company has been facing thousands of individual lawsuits over the years over links to use of the baby powder and ovarian cancer and mesothelioma. As part of the lawsuit, the advocacy group is calling on Johnson & Johnson to rectify its past ad campaigns by creating new adverts that are equitable and have “corrective marketing” that warn Black women of the risks associated with the product.Read the full articles here: Diversity in Clinical Trials: Tackling the Issues in Alzheimer's Research at AAIC 2021Black Women's Group Launches Lawsuit Against Johnson & Johnson Over Targeted Baby Powder AdsFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this episode we share a recording of the AAIC Highlights live plenary session, organised and delivered as part of the conference on 30th July. Session chairs Dr Rebecca Edelmayer & Dr Percy Griffin from Alzheimer's Association speak with panellists Wagner Brum, Karen Dorsman, Alexander Ehrenberg, Dr Maureen Okafor and Dr Anna Volkmer To see the live recording of this session, and more from the conference visit https://www.alz.org/aaic Details on the guest from this recording, and a full transcription can be found on our website - https://www.dementiaresearcher.nihr.ac.uk/podcasts Thank you to Alzheimer's Association for giving us permission to share this recording - please note that this audio should not be copied or duplicated, and the views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of the Alzheimer's Association. _________________________ Finally, please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. Register on our website to receive your weekly bulletin, and to access more great content – blogs, science, career support + much more https://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

Adam Smith narrates his blog written for NIHR Dementia Researcher. In a change to our usual AAIC review format, Adam has narrated his blog for our podcast. He shares the top stories from the week, discusses the platform and his own highlights. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/podcast-aaic-2021-highlights/ If you would like to write for us, drop us a line, we're always on the look out for new bloggers http://www.dementiaresearcher.nihr.ac.uk

Usually at this time of year you would be expecting our daily Alzheimer's Association International Conference Round-up Podcasts - where we bring together ECRs and people attending to share their highlights. Unfortunately, this year, due time-zones and guest availability, it didn't work out. So instead, we asked Adam Smith to write and narrate a blog to share the main highlights and his own favourite sessions from the week. If you missed the conference, don't worry, it isn't too late to register and the content will be available for the next 30 days (to end August 2021) To book your place visit - https://www.alz.org/aaic Join ISTAART to get a free online ticket - https://www.alz.org/istaart using the code AAIC2021 to get 50% discount on membership. The text from this blog is available here https://www.dementiaresearcher.nihr.ac.uk/podcast-aaic-2021-highlights You will find a bio on Adam Smith and a link to his twitter feed, for more AAIC highlights here: https://www.dementiaresearcher.nihr.ac.uk/podcast-profile-adam-smith/ https://twitter.com/BetterResearch _________________________ Finally, please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. Register on our website to receive your weekly bulletin, and to access more great content – blogs, science, career support + much more https://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

In this episode, Ayesha discusses a set of recommendations for use of the new FDA-approved Alzheimer's treatment Aduhelm (aducanumab) published by an expert panel, which was shared at the Alzheimer's Association International Conference (AAIC) 2021 this week. Ayesha and the team talked about the controversial approval of the drug, with lingering questions about its clinical benefit despite having the ability to reduce amyloid plaques as an anti-amyloid monoclonal antibody. It appears that clinicians and scientists in the field have embraced the treatment for the most part and are working towards developing clear guidelines and an infrastructure for the drug's use in the goal of helping patients that could most benefit from the treatment.The team also talked about Pfizer's expanded recall of its smoking cessation drug Chantix, which now involves 12 lots. The recall is over the finding of higher than acceptable levels of a potentially carcinogenic nitrosamine in the batches of Chantix tablets produced between 2019 and 2021. Pfizer and the FDA maintain that the benefit of the medication outweighs the risks and that patients should continue using the drug, which is intended for short-term use. Long-term exposure to high amounts of nitrosamines has been linked to cancer-causing effects. The team talked about the increasing findings of impurities in drug manufacturing leading to similar recalls for other drugs recently, and how pharmacists and care providers should be more informed about them to help patients navigate the recalls.Read the full articles here: AAIC 2021 Coverage: Expert Panel Unveils Recommendations for Biogen's AduhelmChantix Recall: Pfizer Expands Withdrawal of Smoking Cessation Drug Over Carcinogen ConcernsFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this weeks podcast, Adam Smith speaks with Alzheimer's Association Director, Scientific Programs and Outreach, Dr Claire Sexton. Discussing this years Alzheimer's Association International Conference (AAIC) 16-30 July 2021. Taking place in-person in Denver, Colorado, USA and online - the world's leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer's disease. Hear how the conference has adapted to ensure that vital science continues to be shared. How the new hybrid conference will work, get information on the themes and plenary speakers and how to get tickets. To book your place visit - https://www.alz.org/aaic Join ISTAART to get a free online ticket - https://www.alz.org/istaart A transcript of this podcast is also available here https://www.dementiaresearcher.nihr.ac.uk/podcast-aaic-2021-preview Dr Claire Sexton Bio https://www.dementiaresearcher.nihr.ac.uk/profile-dr-claire-sexton/ Adam Smith Bio https://www.dementiaresearcher.nihr.ac.uk/podcast-profile-adam-smith/ _________________________ Like what you hear? Then we have a favour to ask... Dementia Researcher is nominated in the 2021 Peoples Choice Podcast Awards - to get through round one, we need your votes - please head over to https://www.podcastawards.com/app/signup - complete the short registration form, and then select Dementia Researcher in the Medicine & Science and Peoples Choice categories (don't worry, you don't have to do any of the others) - hit submit, and verify - JOB DONE Winning this award would be a great way to thank and recognise the contribution of all our hosts and guests who give up their time freely, to share their science and career tips, and to support ECRs to succeed and to raise the profile of Dementia Research. _________________________ Finally, please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. Register on our website to receive your weekly bulletin, and to access more great content – blogs, science, career support + much more https://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

In this week show, Adam Smith is joined by an extended panel of early career dementia researchers, to discuss their highlights from the AAIC Neuroscience Next Conference. AAIC Neuroscience Next organised by the Alzheimer’s Association was a global, no-cost virtual conference taking place on the 9-10th November 2020. It showcased the work of students and early career investigators in cognitive, computational, behavioural, and other areas of neuroscience research. In addition to the scientific presentations, attendees were given access to information on funding and career workshops and provided with networking opportunities. The panellists for this show are (for the first time) all from outside the UK. We were delighted to be joined by: Lindsay Welikovitch a PhD Student from McGill University, Canada (soon to be Dr having recently successfully defended her thesis). Courtney Kloske, PhD Student from the University of Kentucky, USA. Vee Balendra a Medical Student from St James School of Medicine, USA. Dr Wade Self a Postdoctoral Fellow at The University of Chicago, USA. João Pedro Ferrari Souza a MD and PhD Student from Federal University of Rio Grande do Sul, Brazil. _____________________________________________________________________ You can find out more about our panellists, and their work on our website: www.dementiaresearcher.nihr.ac.uk A transcript of this podcast is also available here https://www.dementiaresearcher.nihr.ac.uk/podcast-aaic-neuroscience-next-conference-roundup _____________________________________________________________________ If you missed the live conference, don’t worry – ISTAART members receive extended access to all content through 10th December 2020 (30 days for non-members who have already registered). For details on ISTAART and the new PIA to Elevate Early Career Researchers visit: www.alz.org/istaart _____________________________________________________________________ Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

To receive CE Credit for this activity please go to www.academiccme.com/ADpodcast and complete the evaluation.

Shanti and Eliot talk to Dr. Josè Luis Molinuevo of the BarcelonaBeta Brain Research Center about his experience at AAIC, and the presentation he gave on biomarkers.

在近期的国际阿尔茨海默病协会国际会议（AAIC 2020）上，美国和瑞典研究团队公布了一项最新研究成果：只需要采血4毫升，对受试者体内的磷酸化tau蛋白P-tau217进行检测，就能准确诊断AD，诊断的准确率可达89-98%！验血诊断不仅准确，还可以区分AD和其它神经退行性疾病，而且部分早发型家族性AD患者在出现症状20年前，体内P-tau217的水平就明显升高，验血诊断可以提早确诊这类患者！研究成果同步发表在《美国医学会杂志》（JAMA）上。

在近期的国际阿尔茨海默病协会国际会议（AAIC 2020）上，美国和瑞典研究团队公布了一项最新研究成果：只需要采血4毫升，对受试者体内的磷酸化tau蛋白P-tau217进行检测，就能准确诊断AD，诊断的准确率可达89-98%！验血诊断不仅准确，还可以区分AD和其它神经退行性疾病，而且部分早发型家族性AD患者在出现症状20年前，体内P-tau217的水平就明显升高，验血诊断可以提早确诊这类患者！研究成果同步发表在《美国医学会杂志》（JAMA）上。

This week we are recording a daily podcast, sharing all the news and highlights from this year’s Alzheimer's Association International ‘Virtual’ Conference. Day Four “Public Health; Dementia Care and Psychosocial Factors; Dementia Care Practice” – Adam Smith is joined by Dr Riona McArdle, Research Associate from Newcastle University, Dr Byron Creese, Senior Research Fellow from Newcastle University and Dementia Care Consultant Esther Wiskerke. This is the last of our AAIC 2020 podcasts. All the content from this conference will be available for 30 days for those who are registered by the 31st July (60 days for ISTAART Members)visit: https://www.alz.org/aaic/registration.asp Checkout the twitter feed with #AAIC20 to find more news from the world largest dementia conference. ______________________________________________ This podcast series is brought to you by Dementia Researcher. You can find out more about our panellists, and their work on our website www.dementiaresearcher.nihr.ac.uk. A transcript of this podcast is also available here https://www.dementiaresearcher.nihr.ac.uk/podcasts ______________________________________________ You can now find our podcasts on your preferred smart home speaker – just ask it for the “Dementia Researcher Podcast”

This week we are recording a daily podcast, sharing all the news and highlights from this year’s Alzheimer's Association International ‘Virtual’ Conference. Day Three “Clinical Manifestations; Drug Development” – Adam Smith is joined by Dr Anna Volmer, Speech & Language Therapist and academic at University College London, Danielle Wilson, Commercialisation Lead at the UK Dementia Research Institute at Imperial College London and Dr Leonidas Chouliaras, Psychiatrist and NIHR Clinical Lecturer at University of Cambridge and Cambridgeshire and Peterborough NHS Foundation Trust.. Check back at this time tomorrow for news from day four, and checkout the twitter feed with #AAIC20 to find more. All the content from the AAIC Conference will be available for free for 30 days after the conference (60 days for ISTAART Members), register now at https://www.alz.org/aaic/overview.asp ______________________________________________ This podcast series is brought to you by Dementia Researcher. You can find out more about our panellists, and their work on our website www.dementiaresearcher.nihr.ac.uk. A transcript of this podcast is also available here https://www.dementiaresearcher.nihr.ac.uk/podcasts ______________________________________________ You can now find our podcasts on your preferred smart home speaker – just ask it for the “Dementia Researcher Podcast” This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

This week we are recording a daily podcast, sharing all the news and highlights from this year’s Alzheimer's Association International ‘Virtual’ Conference. Day Two “Biomarkers” – Adam Smith is joined by Dr James Quinn, Research Fellow, from Massachusetts General Hospital, Rory Boyle, PhD Candidate from Trinity College Dublin and Courtney Kloske, Doctoral Candidate at the University of Kentucky. Check back at this time tomorrow for news from day three, and checkout the twitter feed with #AAIC20 to find more. ______________________________________________ This podcast series is brought to you by Dementia Researcher. You can find out more about our panellists, and their work on our website www.dementiaresearcher.nihr.ac.uk. A transcript of this podcast is also available here https://www.dementiaresearcher.nihr.ac.uk/podcasts ______________________________________________ You can now find our podcasts on your preferred smart home speaker – just ask it for the “Dementia Researcher Podcast” This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

This week we are recording a daily podcast, sharing all the news and highlights from this year’s Alzheimer's Association International ‘Virtual’ Conference. Day One “Basic Science and Pathogenesis” – Dr Megan O’Hare is joined by Professor Louise Serpell, from the University of Sussex, Dr Emily Maguire from the UK Dementia Research Institute at Cardiff University and Dr Lindsay Sinclair from University of Bristol. Check back at this time tomorrow for news from day two, and checkout the twitter feed with #AAIC20 to find more. ______________________________________________ This podcast series is brought to you by Dementia Researcher. You can find out more about our panellists, and their work on our website www.dementiaresearcher.nihr.ac.uk. A transcript of this podcast is also available here https://www.dementiaresearcher.nihr.ac.uk/podcasts ______________________________________________ You can now find our podcasts on your preferred smart home speaker – just ask it for the “Dementia Researcher Podcast” This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

This week Shanti is joined by Dr. James Kupiec, Chief Medical Officer at ProMIS Neurosciences. Shanti and Dr. Kupiec do a deep dive on Biomarkers and discuss recent research coming out of AAIC.

Claire E. Day, Chief Program Officer, Alzheimer's Association Northern California and Northern Nevada Chapter, joins us to share updates from this year's Alzheimer's Association International Conference®. --- Send in a voice message: https://anchor.fm/caring-conversations/message

Claire E. Day, Chief Program Officer, Alzheimer's Association Northern California and Northern Nevada Chapter, joins us to share updates from this year's Alzheimer's Association International Conference®. --- Send in a voice message: https://anchor.fm/caring-conversations/message

This week Shanti and Dr. Johanne Kaplan recap AAIC 2019 and discuss the exciting data that came out of the conference. For more information check out https://promisneurosciences.com/

This week we are recording a daily podcast, sharing all the news and highlights from this years Alzheimer's Association International Conference in Los Angeles. Day Four (Final Day) - Adam Smith is joined by Dr James Pickett from Alzheimer's Society, Dr Claire Lancaster from the University of Oxford and Dr Emily Maguire from the UK Dementia Research Institute at Cardiff University. Thank you to everyone who has contributed to these podcasts and for listening. We hope they have been useful and interesting. The AAIC is a great event for Early Career Researchers, so we hope to see you there next year in Amsterdam. To get more news on the conference, visit their twitter feed with #AAIC19.

This week we are recording a daily podcast, sharing all the news and highlights from this years Alzheimer's Association International Conference in Los Angeles. Day Two - Adam Smith is joined by Dr Sara Imarisio from Alzheimer's Research UK, Riona McArdle from Newcastle University and Dr Astrid Suchy-Dicey from Washington State University. Check back at this time tomorrow for news from day two, and checkout the twitter feed with #AAIC19 to find more.

This week we are recording a daily podcast, sharing all the news and highlights from this years Alzheimer's Association International Conference in Los Angeles. Day Three - Adam Smith is joined by Robin Brisbourne from Alzheimer's Research UK, Dr Lucy Stirland from The University of Edinburgh and Thomas Doherty from Syneos Health. Check back at this time tomorrow for news from day four, and checkout the twitter feed with #AAIC19 to find more.

This week we are recording a daily podcast, sharing all the news and highlights from this years Alzheimer's Association International Conference in Los Angeles. Day One - Adam Smith is joined by Dr Clare Walton from Alzheimer's Society, Sarah Gregory from The University of Edinburgh and Dr James Quinn from Harvard Medical School. Check back at this time tomorrow for news from day two, and checkout the twitter feed with #AAIC19 to find more.

This week Shanti and Johanne preview AAIC and discuss what the hot topics at the conference are expected to be.

Sharon and Tia Powell, MD will discuss bringing joy into dementia caregiving. There is a lot of life between diagnosis and end stages and we need to live with joy. Sharon Hall cares for her mother and her husband. Her husband has FTD and lives at home. Sharon is an active advocate for FTD and those families living with the diagnosis. Dr. Tia Powell directs the Center for Bioethics and Masters' in Bioethics at Montefiore Health Systems and Albert Einstein College of Medicine. She holds the Shoshanah Trachtenberg Frackman chair in biomedical ethics and is Professor of Epidemiology and Psychiatry. Her bioethics scholarship focuses on dementia, public health policy, end of life care, and bioethics education. She served four years as Executive Director of the New York State Task Force on Life and the Law, the state bioethics commission. She has worked with the National Academies of Medicine on many projects, and served as an advisor to the CDC, and to Health and Human Services and its National Alzheimer's Project Act. She is frequently invited to speak at professional meetings (APA, ASBH, AAIC) at medical schools (Albert Einstein, Columbia, Cornell, Harvard, NYU, Yale), and colleges (Vassar, Princeton). She is a board-certified psychiatrist and Fellow of the New York Academy of Medicine, the American Psychiatric Association and The Hastings Center. --- Send in a voice message: https://anchor.fm/caring-conversations/message

Sharon and Tia Powell, MD will discuss bringing joy into dementia caregiving. There is a lot of life between diagnosis and end stages and we need to live with joy. Sharon Hall cares for her mother and her husband. Her husband has FTD and lives at home. Sharon is an active advocate for FTD and those families living with the diagnosis. Dr. Tia Powell directs the Center for Bioethics and Masters' in Bioethics at Montefiore Health Systems and Albert Einstein College of Medicine. She holds the Shoshanah Trachtenberg Frackman chair in biomedical ethics and is Professor of Epidemiology and Psychiatry. Her bioethics scholarship focuses on dementia, public health policy, end of life care, and bioethics education. She served four years as Executive Director of the New York State Task Force on Life and the Law, the state bioethics commission. She has worked with the National Academies of Medicine on many projects, and served as an advisor to the CDC, and to Health and Human Services and its National Alzheimer's Project Act. She is frequently invited to speak at professional meetings (APA, ASBH, AAIC) at medical schools (Albert Einstein, Columbia, Cornell, Harvard, NYU, Yale), and colleges (Vassar, Princeton). She is a board-certified psychiatrist and Fellow of the New York Academy of Medicine, the American Psychiatric Association and The Hastings Center. --- Send in a voice message: https://anchor.fm/caring-conversations/message

In this podcast I am joined with Terry from the Australian Anti Ice Campaign (AAIC) to talk about how everyone can help support this company and to put a freeze on ICE. To learn more about this terrible drug check out episode #7 with Everyln and Anthea who are also from the AAIC.   https://www.facebook.com/groups/1437222979686630/ https://www.australianantiicecampaign.org.au   Sponsors:Bung Pai Thai Massage: https://www.facebook.com/BungPaiThaiMassage/  Proactive Self Defence: https://www.facebook.com/proactiveselfdefencemelbourne/  https://proactiveselfdefence.com  Ray White - Mill Parkhttps://raywhitemillpark.com.au  For more information about the podcast and what is coming up check out the Facebook page: https://www.facebook.com/AdamRoachhost/  email: adroach1@hotmail.com 

In this episode I talk to Everlyn and Anthea from the Australian Anti Ice Campaign (AAIC).This really is a must listen to everyone out there to learn what this drug is doing to people and how it can be stopped by the help of the community and people like Everlyn and Anthea. They talk about what makes ice so addictive and how people are getting tricked into taking it, especially teenagers.There mission is to really spread the message that “not even once and to put the freeze on ice and to stop it before it even starts”. A message that needs to be heard and seen everywhere. To find out more information about AAIC and how you can help click on th link: https://australianantiicecampaign.org.au   Sponsors: Bung Pai Thai Massage: https://www.facebook.com/BungPaiThaiMassage/  Proactive Self Defence: https://www.facebook.com/proactiveselfdefencemelbourne/  https://proactiveselfdefence.com  For more information about the podcast and what is coming up check out the Facebook page: https://www.facebook.com/AdamRoachhost/  email: adroach1@hotmail.com 

This is our fourth and final podcasts recorded on location at the Alzheimer Association International Conference (AAIC) in Chicago. Each day we have been bringing you news and information from our panellists who are all presenting and attending the world largest dementia conference. Adam Smith the Dementia Researcher website Programme Lead for the NIHR is again hosting and today is joined by Katy Stubbs from Alzheimer’s Research UK, Nicholas Firth from University College London and James Quinn from THE University of Manchester. The panel discuss their work, and today’s highlights, including the news from Biogen and Eisai over the exciting trial results of #BAN2401, how the Gut, sleep and environmental pollutants could be important in #dementia – and James talks about Tau. We hope you enjoyed these podcast, from #AAIC18 – our next podcast will be out on Monday 6th August, when we will resume our usual fortnightly schedule. Please subscribe to our feed and share with your colleagues and friends using #ECRDementia.

This is the third and penultimate of our podcasts recorded on location at the Alzheimer Association International Conference (AAIC) in Chicago. Each day we will be bringing you news and information from our panellists who are all presenting and attending the world largest dementia conference. Adam Smith the Dementia Researcher website Programme Lead for the NIHR is again hosting and today is joined by Oz Ismail (aka Birthday Boy) and Yolanda Ohene both PhD Students at University College London and Isabel Castanho a PhD Student at Exeter University Medical School. The panel discuss their own presentations, and just how much the brain is like a fantastic water park. We also discuss their highlights from the third day here at the AAIC, including sessions on ‘Microbiome and the brain’ and the latest research on the impact of circadian rhythms. Oz and Isabel also share their experiences as ISTAART volunteers, whilst also encouraging others to consider supporting AAIC19. Tune in again tomorrow for day four, and our next panel.

This is the first of our podcasts recorded on location at the Alzheimer Association International Conference (AAIC) in Chicago. Each day we will be bringing you news and information from our panellists who are all presenting and attending the world largest dementia conference. Today’s podcast is hosted by our own programme lead Adam Smith, he is joined by Dr Aoife Kiely from the Alzheimer’s Society, Dr Jack Rivers-Auty from Manchester University and Riona McArdle a PhD student from Newcastle University. The panel discuss their own presentations, the exuberant opening ceremony performance by the Chicago Boyz acrobatic team @ChicagoBoyzTeam, the fantastic research by Lennart Mucke from the Glasdstone institute on ‘Aberent Network Activity in AD, and preclinical investigation to clinical trials’, and other presentations and posters that caught their eye (including some scepticism on beers value in preventing dementia, and ‘Plaque-Out’ a nutraceutical supplement drink claiming to reduce b-amaloid (yes that’s how they spelt it on their sign) plaque in up to 41% of patients. Tune in again tomorrow for day two, and our next panel.

This is the second of our podcasts recorded on location at the Alzheimer Association International Conference (AAIC) in Chicago. Each day we will be bringing you news and information from our panellists who are all presenting and attending the world largest dementia conference. Today’s podcast is again hosted by our own programme lead Adam Smith (he is hosting them all week), he is joined by Sarah Gregory a study coordinator for the EPAD and Prevent studies at the University of Edinburgh, Nika Seblova a PhD student working on the casual effects of education on life-course cognitive ability and dementia at the Karolinska Institute in Sweden and Ivanna Pavisic who is a PhD student at University College London focusing on different neurocognitive assessments. The panel discuss their own presentations, if Chicago Pizza is real pizza…and their highlights from the second fantastic day here at the AAIC, including sessions on ‘Multimodal strategies for dementia prevention’ and the ‘aging brain and the risk for Alzheimer’s disease’ by Denise C Park at the University of Texas. We also discuss the effects of television on cognition and the fantastic ISTAART breakfast session by the Alliance of Women Alzheimer’s Researchers also known as AWARE discussing mentorship Tune in again tomorrow for day three, and our next panel.

At the Alzheimer’s Association International Conference (AAIC; London, UK, 16–20 July 2017), we sat down with Megan Zuelsdorff, University of Wisconsin School of Medicine and Public Health (WI, USA), to hear more about her work on lifetime stress experiences, racial disparities and cognitive health. Part of the Wisconsin Registry for Alzheimer's Prevention (WRAP) Study, Megan and colleagues examined the impact of lifetime stressful experiences on cognition. They found that a greater number of stressful events was associated with poorer late-life cognitive function for all study participants. In addition, African Americans experienced over 60% more stressful events than non-Hispanic White participants during their lifetimes, and these experiences were linked to poorer memory and thinking skills in older age. The researchers determined that, in African Americans, each stressful experience was equivalent to approximately 4 years of cognitive aging. In this interview, we hear more about the study and its implications: "Among African Americans in our study, adverse events across the lifespan predict cognitive function more strongly than established risk factors including age, education, and the APOE-e4 Alzheimer's risk gene," Megan said. "Adversity is a clear contributor to racial disparities in cognitive aging, and further study is imperative." You can view more podcasts, plus the latest news and interviews with experts across neurology and neuroscience, at www.neuro-central.com.

Whilst at the Alzheimer’s Association International Conference in London (AAIC; UK, 16–20 July 2017), Lauren Pulling (Editor, Neuro Central) sat down with Kim Mueller, a researcher from the Wisconsin Alzheimer’s Institute (University of Wisconsin-Madison, WI, USA), whose abstract had been highlighted by the Association as one of note. The work presented at AAIC investigated whether early memory decline correlates with changes in everyday speech. The results showed that subtle changes in speech – e.g., the use of short sentences, more pronouns, more frequent pauses and filler words – increased in line with development of early mild cognitive impairment, and therefore, further down the line, could be used as a marker for Alzheimer’s disease. In this podcast, Kim discusses the study and its implications, including how these findings could one day be translated into new – potentially mobile – technology for at-home screening and disease monitoring. You can view more podcasts, plus the latest news and interviews with experts across neurology and neuroscience, at www.neuro-central.com.

Hablamos en “Al Mediodía de SPR”con la doctora María Carrillo, de la Asociación de Alzheimer, sobre los datos más recientes acerca este padecimiento. La doctora Carrillo está asistiendo a la Conferencia Internacional de la Asociación de Alzheimer (AAIC) en Londres y desde ahí nos concedió esta breve entrevista.

The plenary sessions at Alzheimer’s Association International Conference (AAIC; London, UK, 16–20 July 2017) have featured fantastic talks from leading experts in the field, so far addressing topics including biomarkers, targeting beta-amyloid, genetics, big data and the neurotoxicity of tau. While at the conference, Lauren Pulling (Editor, Neuro Central) sat down with Julie Williams, Professor of Neuropsychological Genetics at Cardiff University (UK) and the Chief Scientific Advisor of the Welsh Government, to hear more about her work on susceptibility genes in Alzheimer’s disease (AD). You can view more podcasts, plus the latest news and interviews with experts across neurology and neuroscience, at www.neuro-central.com.

There's plenty of talk on radio, but with 20twenty you'll find Life, Culture & Current events from a Biblical perspective. Interviews, stories and insight you definately won't hear in the mainstream media. This feed contains selected content from 20twenty, heard every weekday morning. See www.vision.org.au for more details Help Vision to keep 'Connecting Faith to Life': https://vision.org.au/donate See omnystudio.com/listener for privacy information.